SEARCH:   Advanced

Blood, 15 May 2005, Vol. 105, No. 10, pp. 4115-4119. Prepublished online as a Blood First Edition Paper on January 25, 2005; DOI 10.1182/blood-2004-11-4299. This Article Full Text (PDF) All Versions of this Article: 2004-11-4299v1 105/10/4115    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rondelli, D. Articles by Hoffman, R. Search for Related Content PubMed PubMed Citation Articles by Rondelli, D. Articles by Hoffman, R. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 12, 2004 Accepted January 13, 2005 Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate or high risk patients with myelofibrosis with myeloid metaplasia Damiano Rondelli*, Giovanni Barosi, Andrea Bacigalupo, Josef T Prchal, Uday Popat, Emilio P Alessandrino, Jerry L Spivak, B D Smith, Hans G Klingemann, Steven Fruchtman, and Ronald Hoffman University of Illinois at Chicago, Chicago, IL, USA IRCCS Policlinico S. Matteo, Pavia, Italy Ospedale S. Martino, Genova, Italy Baylor College of Medicine, Houston, TX, USA Johns Hopkins University, Baltimore, MD, USA Rush University, Chicago, IL, USA Mount Sinai School of Medicine, New York, NY, USA * Corresponding author; email: drond{at}uic.edu. Twenty-one patients with myelofibrosis with myeloid metaplasia (MMM), median age 54 yrs (range: 27-68), were prepared with a reduced intensity conditioning (RIC) regimen and received an allogeneic marrow (n=3) or peripheral blood stem cell (n=18) transplant from HLA-matched related (n=18) or unrelated (n=2), or 1 Ag-mismatched related (n=1) donors. RIC regimens included fludarabine/total body irradiation 200cGy (n=5) or 450 cGy (n=1), fludarabine/melphalan (n=7), thiotepa/cyclophosphamide (n=7) and thiotepa/fludarabine (n=1). At the time of transplant all the patients were at intermediate (n=13) or high risk (n=8), according to the Dupriez classification. Nineteen patients had grade III/IV marrow fibrosis. All the patients achieved full engraftment but one. Posttransplant chimerism analysis showed >95% donor cells in 18 patients, while 2 patients achieved complete donor chimerism after donor leukocyte infusion (DLI). Acute GVHD grade II-IV was observed in 7 patients, grade III-IV in 2, and extensive chronic GVHD in 8 of 18 evaluable patients. Three patients died from acute GVHD, infection and relapse, respectively. Eighteen patients are alive 12 to 122 (median: 31) months after transplant and 17 are in remission (1 after a second transplant). The use of RIC regimens in allogeneic stem cell transplantation results in prolonged survival in intermediate/high risk MMM patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. S. Tam, H. Kantarjian, J. Cortes, A. Lynn, S. Pierce, L. Zhou, M. J. Keating, D. A. Thomas, and S. Verstovsek Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis J. Clin. Oncol., November 20, 2009; 27(33): 5587 - 5593. [Abstract] [Full Text] [PDF] A. Quintas-Cardama, H. M. Kantarjian, T. Manshouri, D. Thomas, J. Cortes, F. Ravandi, G. Garcia-Manero, A. Ferrajoli, C. Bueso-Ramos, and S. Verstovsek Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis J. Clin. Oncol., October 1, 2009; 27(28): 4760 - 4766. [Abstract] [Full Text] [PDF] R. A. Mesa How I treat symptomatic splenomegaly in patients with myelofibrosis Blood, May 28, 2009; 113(22): 5394 - 5400. [Abstract] [Full Text] [PDF] A. M. Vannucchi, P. Guglielmelli, and A. Tefferi Advances in Understanding and Management of Myeloproliferative Neoplasms CA Cancer J Clin, May 1, 2009; 59(3): 171 - 191. [Abstract] [Full Text] [PDF] C. S. Tam, L. V. Abruzzo, K. I. Lin, J. Cortes, A. Lynn, M. J. Keating, D. A. Thomas, S. Pierce, H. Kantarjian, and S. Verstovsek The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course Blood, April 30, 2009; 113(18): 4171 - 4178. [Abstract] [Full Text] [PDF] F. Cervantes, B. Dupriez, A. Pereira, F. Passamonti, J. T. Reilly, E. Morra, A. M. Vannucchi, R. A. Mesa, J.-L. Demory, G. Barosi, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood, March 26, 2009; 113(13): 2895 - 2901. [Abstract] [Full Text] [PDF] N. Kroger, H. Alchalby, E. Klyuchnikov, A. Badbaran, Y. Hildebrandt, F. Ayuk, U. Bacher, O. Bock, M. Kvasnicka, B. Fehse, et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation Blood, February 19, 2009; 113(8): 1866 - 1868. [Full Text] [PDF] D. Rondelli Allogeneic hematopoietic stem cell transplantation for myelofibrosis Haematologica, October 1, 2008; 93(10): 1449 - 1450. [Full Text] [PDF] S. Chunduri, S. Gaitonde, S. O. Ciurea, R. Hoffman, and D. Rondelli Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation Haematologica, October 1, 2008; 93(10): 1593 - 1595. [Full Text] [PDF] F. Patriarca, A. Bacigalupo, A. Sperotto, M. Isola, F. Soldano, B. Bruno, M. T. van Lint, A. P. Iori, S. Santarone, F. Porretto, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Haematologica, October 1, 2008; 93(10): 1514 - 1522. [Abstract] [Full Text] [PDF] C. S. Tam, R. M. Nussenzveig, U. Popat, C. E. Bueso-Ramos, D. A. Thomas, J. A. Cortes, R. E. Champlin, S. E. Ciurea, T. Manshouri, S. M. Pierce, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms Blood, September 1, 2008; 112(5): 1628 - 1637. [Abstract] [Full Text] [PDF] F. Passamonti, E. Rumi, M. Caramella, C. Elena, L. Arcaini, E. Boveri, C. Del Curto, D. Pietra, L. Vanelli, P. Bernasconi, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis Blood, April 1, 2008; 111(7): 3383 - 3387. [Abstract] [Full Text] [PDF] A. Rambaldi, T. Barbui, and G. Barosi From Palliation to Epigenetic Therapy in Myelofibrosis Hematology, January 1, 2008; 2008(1): 83 - 91. [Abstract] [Full Text] [PDF] S. O. Ciurea, D. Merchant, N. Mahmud, T. Ishii, Y. Zhao, W. Hu, E. Bruno, G. Barosi, M. Xu, and R. Hoffman Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis Blood, August 1, 2007; 110(3): 986 - 993. [Abstract] [Full Text] [PDF] N. Kroger, A. Badbaran, E. Holler, J. Hahn, G. Kobbe, M. Bornhauser, A. Reiter, T. Zabelina, A. R. Zander, and B. Fehse Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis Blood, February 1, 2007; 109(3): 1316 - 1321. [Abstract] [Full Text] [PDF] R. Hoffman and D. Rondelli Biology and Treatment of Primary Myelofibrosis Hematology, January 1, 2007; 2007(1): 346 - 354. [Abstract] [Full Text] [PDF] R. A. Mesa Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 355 - 362. [Abstract] [Full Text] [PDF] C. Arana-Yi, A. Quintas-Cardama, F. Giles, D. Thomas, A. Carrasco-Yalan, J. Cortes, H. Kantarjian, and S. Verstovsek Advances in the Therapy of Chronic Idiopathic Myelofibrosis Oncologist, September 1, 2006; 11(8): 929 - 943. [Abstract] [Full Text] [PDF] A. Tefferi, G. Barosi, R. A. Mesa, F. Cervantes, H. J. Deeg, J. T. Reilly, S. Verstovsek, B. Dupriez, R. T. Silver, O. Odenike, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT) Blood, September 1, 2006; 108(5): 1497 - 1503. [Abstract] [Full Text] [PDF] A. Tefferi, J. Cortes, S. Verstovsek, R. A. Mesa, D. Thomas, T. L. Lasho, W. J. Hogan, M. R. Litzow, J. B. Allred, D. Jones, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia Blood, August 15, 2006; 108(4): 1158 - 1164. [Abstract] [Full Text] [PDF] A. I. Schafer Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia Blood, June 1, 2006; 107(11): 4214 - 4222. [Abstract] [Full Text] [PDF] U. Popat, A. Frost, E. Liu, Y. Guan, A. Durette, V. Reddy, and J. T. Prchal High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension Blood, May 1, 2006; 107(9): 3486 - 3488. [Abstract] [Full Text] [PDF] R. T. Silver The ABCCs of myelofibrosis Blood, October 15, 2005; 106(8): 2598 - 2599. [Full Text] [PDF] G. Barosi, D. Bordessoule, J. Briere, F. Cervantes, J.-L. Demory, B. Dupriez, H. Gisslinger, M. Griesshammer, H. Hasselbalch, R. Kusec, et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET) Blood, October 15, 2005; 106(8): 2849 - 2853. [Abstract] [Full Text] [PDF] A. Tefferi and T. Barbui bcr/abl-Negative, Classic Myeloproliferative Disorders: Diagnosis and Treatment Mayo Clin. Proc., September 1, 2005; 80(9): 1220 - 1232. [Abstract] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020